Evidence map›Paper›PMID 32556884›Full record

ArticleInvestigational new drugs2021

Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.

Jennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, Joseph A Bokar, Panos Savvides, Neal J Meropol, Joseph Gibbons, Henry Koon, Neelesh Sharma, Lisa Rogers and 7 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Analytical chemistry · 2022
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Jennifer R EadsCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Smitha S KrishnamurthiCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Joel SaltzmanCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Joseph A BokarCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Panos SavvidesSt. Joseph's Hospital and Medical Center, University of Arizona Comprehensive Cancer Center, University of Arizona, Phoenix, AZ, USA.
Neal J MeropolCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Joseph GibbonsCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Henry KoonCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Neelesh SharmaNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Lisa RogersCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
John J PinkCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Yan XuCase Comprehensive Cancer Center, Cleveland State University, Cleveland, OH, USA.
Jan H BeumerUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
John RiendeauCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Pingfu FuCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Stanton L GersonCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA.
Afshin DowlatiCase Comprehensive Cancer Center, Case Western Reserve University, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH, 44106, USA. Afshin.dowlati@case.edu.ORCID 0000-0003-4535-6839
University Hospitals Seidman Cancer Center · USCase Western Reserve University · USCleveland State University · USFlatiron Health (United States) · USNovartis (United States) · USSt. Joseph's Hospital and Medical Center · USUPMC Hillman Cancer Center · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2M
MODULATING BASE EXCISION REPAIR IN TUMOR DRUG RESISTANCER01CA086357 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 2000 to 2008
$2.4M
Methoxyamine and Temozolomide: A Phase I Trial Blocking Base Excision RepairR21CA126149 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 2007 to 2008
$596k
NCI NIH HHS K12 CA076917NCI NIH HHS P30 CA043703NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA086357NCI NIH HHS R21 CA126149
6 · The paper itself

Abstract

Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N

Indexed as

AdultAgedAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveDNA RepairDose-Response Relationship, DrugDrug SynergismFemaleHalf-LifeHumansHydroxylaminesMaleMaximum Tolerated DoseMetabolic Clearance RateMiddle AgedAntineoplastic Agents, AlkylatingHydroxylaminesmethoxyamineTemozolomideDNA repairMethoxyaminePhase ITemozolomideTRC-102

Identifiers

PMID32556884
PMCPMC7744386
OpenAlexW3036205900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.